Fingolimod: brain volume data


As a follow-up to my comment on a previous posting; I predict that if the PPMS trial is positive Fingolimod will be the first drug to be licensed as a neuroprotective therapy in MS.

The following diagram summarises the MRI data published on the impact of Fingolimod on brain atrophy over 2 years.

Please see: Kappos et al. N Engl J Med. 2010 Feb 4;362(5):387-401.

COI: Please note my previous COI statement in relation to Fingolimod.

About the author

Prof G

Professor of Neurology, Barts & The London. MS & Preventive Neurology thinker, blogger, runner, vegetable gardener, husband, father, cook and wine & food lover.

Add comment

By Prof G



Recent Posts

Recent Comments